Alkermes reports encouraging data from Phase III study of Lumryz
During the open-label dose titration and stable dose periods, all participants received Lumryz, showing improved ESS scores.
News
Inhibrx announces positive interim results from HexAgon trial
Day One concludes patient enrolment for tovorafenib’s FIREFLY-2 trial
MEDSIR reports PHERGain and PHERGain-2 trial results for breast cancer
Patient enrolment concludes in Alebund’s Phase III trial of AP301
Nocion completes patient enrolment in Phase IIb ASPIRE trial
Takeda’s Phase II/III trial of TAK-881 meets primary endpoint
Celcuity reports Phase III VIKTORIA-1 trial results for breast cancer
